Table 1 Baseline characteristics of the included patients
Parameter | All patients (n = 39) |
|---|---|
Age, years, median (IQR) | 67 (62–74) |
Sex, n (%) | |
Female | 31 (79.5) |
Male | 8 (20.5) |
Etiology of cirrhosis, n (%) | |
Alcohol | 13 (33.3) |
Viral | 9 (23.1) |
Other | 9 (23.1) |
No cirrhosis | 8 (20.5) |
Child-Pugh stage, n (%) | |
A | 20 (51.3) |
B | 9 (23.1) |
C | 2 (5.1) |
No cirrhosis | 8 (20.5) |
ECOG, n (%) | |
≤1 | 33 (84.6) |
> 1 | 6 (15.4) |
BCLC stage, n (%) | |
B | 3 (7.7) |
C | 34 (87.2) |
D | 2 (5.1) |
Portal vein invasion, n (%) | |
Yes | 20 (51.3) |
No | 19 (48.7) |
Distant metastasis, n (%) | |
Yes | 22 (56.5) |
No | 17 (43.5) |
Immunotherapy agent, n (%) | |
Atezolizumab + Bevacizumab | 22 (56.5) |
Pembrolizumab | 10 (25.6) |
Nivolumab | 7 (17.9) |
Line of systemic treatment, n (%) | |
First | 19 (48.7) |
Second | 12 (30.8) |
Third or higher | 8 (20.5) |
Previous therapy, n (%) | |
Yes | 32 (82.1) |
No | 7 (17.9) |
Subsequent therapy, n (%) | |
Yes | 15 (38.5) |
No | 24 (61.5) |
Number of target lesions, n (%) | |
1 | 6 (15.4) |
2 | 21 (53.8) |
3 | 6 (15.4) |
4 | 4 (10.3) |
5 | 2 (5.1) |
Sum of the sizes of all target lesions, mm, median (IQR) | 61 (49–111) |
AFP, ng/ml, median (IQR) | 141 (15–2548) |
Albumin, g/l, median (IQR) | 31 (28–35) |
Bilirubin, mg/dl, median (IQR) | 1.2 (0.7–2.2) |
INR, median (IQR) | 1.2 (1.1–1.3) |
Creatinine, mg/dl, median (IQR) | 0.8 (0.7–1.1) |